ノボ - novonordisk.co.jp

1 100-0005 2-1-1 Tel: 03-6266-1700 Tel: 0120-180363 : 2018 6 28 ( 6 23 ) PRESS-18-16 78 (ADA) ( 2018 6 22 26 ) U300 ( ) 2 HbA1c 30% ( U100 U200 *) U300 (RWE) CONFIRM 78 (ADA) 4,000 2 6 U300 HbA1c ( p= )1 (* U200 ) U300 30% (p= )1 (ICD-9/10)

2 2 RWE U300 2 37% (p< )1 CONFIRM 2 100-0005 2-1-1 Tel: 03-6266-1700 Tel: 0120-180363 : CONFIRM CONFIRM ( 365 ) 2 4,056 U300( XR) (n = 2,028) 1 GLP-1 U300 6 HbA1c( ) 1 CONFIRM RWE ( CONFIRM ) 3 6 ( HbA1c )

3 CONFIRM 3-6 ( ) 42 ( ) 1 1 7,8 U100 8,9 2012 9 80 61 References 1. Tibaldi J, Haldrup S, Sandberg V, et al. Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM): A 100-0005 2-1-1 Tel: 03-6266-1700 Tel: 0120-180363 : Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in 4,056 Insulin-Na ve Patients with Type 2 Diabetes (T2D) Oral/poster presentation.

4 78th Annual Scientific Sessions of the American Diabetes Asosciation (ADA), Orlando, Florida, US. June 2018. 2. Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008; 8:4. 3. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36:1384-1395. 4. International Hypoglycaemia Study Group. Diagnosis of hypoglycaemia. Available online at Last accessed: June 2018. 5. Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007; 117:868-870. 6. Ahr n B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013; 9:155-163. 7. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance.

5 Clin Pharmacokinet. 2014; 53:787 800. 8. EMA. Tresiba Summary of Product Characteristics. Available at: Last accessed: June 2018. 9. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723 732. 95 79 4 2,700 170 1980